BeyondSpring (NASDAQ:BYSI) Stock Price Down 4.8% – Time to Sell?

BeyondSpring Inc. (NASDAQ:BYSI)’s stock price traded down 4.8% during trading on Friday . The company traded as low as $1.56 and last traded at $1.57. 14,427 shares were traded during trading, a decline of 42% from the average session volume of 24,960 shares. The stock had previously closed at $1.65.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of BeyondSpring in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

BeyondSpring Stock Down 4.8%

The stock’s fifty day moving average price is $1.61 and its 200 day moving average price is $1.65. The stock has a market cap of $64.56 million, a PE ratio of -11.21 and a beta of 0.43.

BeyondSpring (NASDAQ:BYSI) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC boosted its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 16.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 368,682 shares of the company’s stock after purchasing an additional 53,198 shares during the period. Geode Capital Management LLC owned about 0.91% of BeyondSpring worth $601,000 at the end of the most recent reporting period. 40.29% of the stock is owned by hedge funds and other institutional investors.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.